Open AccessOral and Inhaled Ribavirin Treatment for Respiratory Syncytial Virus Infection in Lung Transplant Recipients
Author(s) -
Nitipong Permpalung,
Tany Thaniyavarn,
Jennifer L. Saullo,
Sana Arif,
Rachel Miller,
John M. Reynolds,
Barbara D. Alexander
Publication year - 2020
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000002985
Subject(s) - ribavirin , medicine , gastroenterology , respiratory system , vomiting , mechanical ventilation , virus , hepatitis c virus , immunology
Respiratory syncytial virus (RSV) infection in lung transplant recipients (LTRs) causes mortality rates of 10%-20% despite antiviral therapy. Ribavirin (RBV) has been used to treat RSV-infected LTRs with limited data.